Shorts

Dr Hoehn on a More Equitable Approach to Clinical Trials

A Breakthrough in Renal Cell Carcinoma Treatment

How ctDNA and Genomics Are Changing Modern Oncology

ctDNA: The Future of Detecting Cancer Recurrence

T-Cell Engagers Look Promising in Prostate Cancer

Turning “Negative” PDAC Trials Into Future Breakthroughs

The Flaw in Current Prostate Cancer Biomarkers

Understanding Bone Protective Agents

Test First, Treat Second: ASCO's Updated Approach to Driver Mutation–Negative NSCLC

The “Donut” Pattern of Clinical Trial Enrollment

Strategies for Anemia Management in Myelofibrosis

Financial Barriers Outweigh Race in Clinical Trial Enrollment

Managing Anemia and Transfusion Access Challenges

Predicting Cancer Outcomes with ctDNA Status in Bladder Cancer

PIM Inhibitor Shows Promise in High-Risk Myelofibrosis

More Than a Marker: Behind the Aggressive Nature of CD25+ Leukemias

What’s Needed to Bring Clinical Trials to the Patient

Can GLP-1 Agonists Help Treat Rare Cancers?

Initial Assessments in Metastatic RCC

The Future of Oncology Innovation is Moving to the Community

Medicaid Expansion Saves Lives in Breast Cancer

Understanding Co-Mutations and Real-Time ctDNA Monitoring in Lung Cancer

Developing Novel Alpha-Emitting Agents in Prostate Cancer

The Silent Crisis: Why Oncologists are Burning Out

The Future of Hybrid Healthcare

The Most 'Ripe' Areas for AI in Healthcare Right Now

The Challenge Isn't the Medicine—It's the Operations

Predicting the Future: AI in the Medical Clinic

How AI Could Have Saved More Lives 10 Years Ago

How AI is Revolutionizing Precision Oncology